SHARE
Myasthenia Gravis Market

Myasthenia Gravis Market Forecasts to 2028 – Global Analysis By Type (Ocular Myasthenia Gravis, Congenital Myasthenia Gravis, Generalized Myasthenia Gravis, Transient Myasthenia Gravis) and By Geography

4.0 (94 reviews)
Published: November 2021 ID: SMRC21136
4.0 (94 reviews)
Published: November 2021 ID: SMRC21136

This report covers the impact of COVID-19 on this global market
Loading...

According to Stratistics MRC, the Global Myasthenia Gravis Market is accounted for $1.40 billion in 2020 and is expected to reach $3.00 billion by 2028 growing at a CAGR of 10.0% during the forecast period. Factors such as increasing health care spending, improving health care infrastructure, and growing prevalence of autoimmune disorders are driving the growth of the market. However, limited availability of drugs is hampering the growth of the market.

Myasthenia gravis is a chronic autoimmune neuromuscular disorder that is characterized by variable weakness of the voluntary muscle groups. Muscles that observe eye movement, shoulder & facial muscles, breathing & swallowing and eye lids are the ones that are regularly impacted in myasthenia gravis.

Based on the treatment, the drug treatment/medication segment is anticipated to expand at a rapid pace during the forecast period due to the ongoing research and development activities that are being carried out to improve the efficacy of available medications. By geography, North America is going to have high growth during the forecast period as most of the population in the region are covered under medical and health insurance and hence, are able to afford the expensive medication and therapies for myasthenia gravis.

Some of the key players profiled in the Myasthenia Gravis Market include Medtronic Plc., Novartis AG, Koninklijke Philips N.V., F. Hoffmann-La Roche AG, Boston Scientific Corporation, Valeant Pharmaceuticals International, Inc., Pfizer Inc., Baxter International, Inc., Takeda Pharmaceutical Company Limited, Alexion Pharmaceutical Inc., Shire PLC, CSL Behring, Avadel Pharmaceuticals, PLC. (Flamel Technologies), and Grifols S.A.

Report Coverage

Details

Published Year:

2021

Estimated Market Size in 2020:

USD 1.40 billion

Estimated Period:

2020

Compound Annual Growth Rate (CAGR)  from 2020 to 2028:

10.0%

Predicted 2028 Value:

USD 3.00 billion

Forecast Years:

2021-2028

Tables, Graphs & Figures

161

Chapters Covered:

Type, Diagnosis, Treatment, End User, and Region

Core Drivers and Opportunities:

  • Increasing prevalence of autoimmune disorders
  • Improving health care infrastructure
  • Emergence of biologics

Restraining Factors & Market Threats:

  • Limited availability of drugs
  • High cost of treatment


Types Covered:
• Ocular Myasthenia Gravis
• Congenital Myasthenia Gravis
• Generalized Myasthenia Gravis
• Transient Myasthenia Gravis

Diagnosis Covered:
• Electrodiagnostic
• Imaging
• Edrophonium Tests
• Pulmonary Function Tests
• Blood Tests   

Treatments Covered:
• Drug Treatment/Medication
• Rapid Immunotherapies

End Users Covered:
• Hospitals & Clinics
• Diagnostic Centers
• Academic & Research Institutes

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan       
o China        
o India       
o Australia 
o New Zealand
o South Korea
o Rest of Asia Pacific   
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2019, 2020, 2021, 2025, and 2028
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

 

Key Questions Answered In The Report

The Global Myasthenia Gravis Market is majorly driven by the increasing health care spending, improving health care infrastructure, and growing prevalence of autoimmune disorders.

The hospitals & clinics segment is growing at a highest CAGR owing to the large patient pool and in hospital settings and specialty clinics.

North America dominated with a significant market share due to the presence of established research and development facilities.

Asia Pacific market is growing at a highest CAGR owing to the increasing investments in the healthcare sector by the governments and manufacturers in the region.

Key players in Myasthenia Gravis Market include Medtronic Plc., Novartis AG, Koninklijke Philips N.V., F. Hoffmann-La Roche AG, Boston Scientific Corporation, Valeant Pharmaceuticals International, Inc., Pfizer Inc., Baxter International, Inc., Takeda Pharmaceutical Company Limited, Alexion Pharmaceutical Inc., Shire PLC, CSL Behring, Avadel Pharmaceuticals, PLC. (Flamel Technologies), and Grifols S.A.

Select License Type

NEW YEAR SALE
Allows one person to have access to the ordered product.The ordered product cannot be distributed to anyone else.
Allows the ordered product to be shared among a maximum of 5 people within your organisation.
Allows the product to be shared among all employees of your organisation at one particular location.
Allows the product to be shared among all employees of your organisation regardless of their geographical location.

WHY CHOOSE US ?

Assured Quality

Assured Quality

Best in class reports with high standard of research integrity

24X7 Research Support

24X7 Research Support

Continuous support to ensure the best customer experience.

Free Customization

Free Customization

Adding more values to your product of interest.

Safe and Secure Access

Safe & Secure Access

Providing a secured environment for all online transactions.

Trusted by 600+ Brands

Trusted by 600+ Brands

Serving the most reputed brands across the world.

Testimonials